The characteristics of Aspergillus fumigatus mycetoma development: Is this a biofilm?

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Mowat, Eilidh ^a   Williams, Craig ^b   Jones, Brian ^c   McChlery, Susan ^c   Ramage, Gordon ^c  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

Author keywords

Aspergillus fumigatus; Biofilm

Indexed keywords

ABC TRANSPORTER; ECHINOCANDIN; POLYENE; PROTEIN AFUMDR4; PYRROLE; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BIOFILM; CANDIDA ALBICANS; CELL DENSITY; CELL STRUCTURE; CELL VIABILITY; FUNGAL MORPHOLOGY; FUNGAL SPORE GERMINATION; FUNGAL VIRULENCE; FUNGUS GROWTH; GENOTYPE; MICROARRAY ANALYSIS; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; MYCETOMA; NONHUMAN; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; DRUG EFFECT; EXTRACELLULAR MATRIX; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; REVIEW;

ASPERGILLUS FUMIGATUS; FUNGI;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BIOFILMS; EXTRACELLULAR MATRIX; HUMANS; MICROBIAL VIABILITY; MYCETOMA;

EID: 67651101026     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802238834     Document Type: Article

References (48)

1. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 (Suppl. 1): S207-238.
2. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609-622.
3. Ellis M, Richardson M, de Pauw B. Epidemiology. Hosp Med 2000; 61: 605-609.
4. Rivera A, Hohl T, Pamer EG. Immune responses to Aspergillus fumigatus infections. Biol Blood Marrow Transplant 2006; 12: 47-49.
5. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37: 173-180.
6. Brakhage AA: Systemic fungal infections caused by Aspergillus species: Epidemiology, infection process and virulence determinants. Curr Drug Targets 2005; 6: 875-886.
7. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
8. de Almeida MB, Bussamra MH, Rodrigues JC. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev 2006; 7: 67-72.
9. Shibuya K, Ando T, Hasegawa C, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother 2004; 10: 138-145.
10. Filler SG, Sheppard DC. Fungal invasion of normally nonphagocytic host cells. PLoS Pathog 2006; 2: E129.
11. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam i Micol 2001; 18: 163-170.
12. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: An update. Eukaryot Cell 2005; 4: 633-638.
13. Beauvais A, Schmidt C, Guadagnini S, et al. An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell Microbiol 2007; 9: 1588-1600.
14. Villena GK, Gutierrez-Correa M. Production of cellulase by Aspergillus niger biofilms developed on polyester cloth. Lett Appl Microbiol 2006; 43: 262-268.
15. Mowat E, Butcher J, Lang S, et al. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol 2007; 56: 1205-1212.
16. Donlan RM. Biofilms: Microbial life on surfaces. Emerg Infect Dis 2002; 8: 881-890.
17. Costerton JW, Lewandowski Z, Caldwell DE, et al. Microbial biofilms. Annu Rev Microbiol 1995; 49: 711-745.
18. Gutierrez-Correa M, Villena GK. Surface adhesion fermentation: A new fermentation category. Revista Peru Biol 2003; 10: 113-124.
19. Villena GK, Gutierrez-Correa M. Morphological patterns of Aspergillus niger biofilms and pellets related to lignocellulolytic enzyme productivities. Lett Appl Microbiol 2007; 45: 231-237.
20. Villena GK, Moreno P, Gutierrez-Correa M. Cellulase production by fungal biofilms on polyester cloth. AG Biotech 2001; 12: 32-35.
21. Mowat E, Williams C, Ramage G. Susceptibility profiles and in vitro pharmacokinetics of developing Aspergillus fumigatus multicellular structures (poster no. 7). In Advances Against Aspergillosis. Miami, Florida, 2008.
22. Chandrasekar PH, Manavathu EK. Do Aspergillus species produce biofilm? Future Microbiol 2008; 3: 19-21.
23. Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 2002; 214: 95-100.
24. Nobile CJ, Mitchell AP. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 2006; 8: 1382-1391.
25. Chandra J, Kuhn DM, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-5394.
26. Blankenship JR, Mitchell AP. How to build a biofilm: A fungal perspective. Curr Opin Microbiol 2006; 9: 588-594.
27. Kamai Y, Chiang LY, Lopes Bezerra LM, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol 2006; 44 (Suppl. 1): S115-117.
28. Al-Fattani MA, Douglas LJ. Biofilm matrix of Candida albicans and Candida tropicalis: Chemical composition and role in drug resistance. J Med Microbiol 2006; 55: 999-1008.
29. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-888.
30. Ramage G, Lopez-Ribot JL. Chapter 11. Fungal biofilms and drug resistance. In: San Blas G, Calderone RA (eds), Pathogenic Fungi: Host Interactions and Emerging Strategies for Control. Caister Academic Press, Washington DC, USA. 2004.
31. Ramage G, VandeWalle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46: 3634-3636.
32. D'Enfert C. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr Drug Targets 2006; 7: 465-470.
33. Ramage G, Bachmann S, Patterson TF, et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49: 973-980.
34. Guarro J, Llop C, Aguilar C, Pujol I. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob Agents Chemother 1997; 41: 2760-2762.
35. Krishnan S, Manavathu EK, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 2005; 55 914-920.
36. Antachopoulos C, Meletiadis J, Roilides E, et al. Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol 2006; 44: 553-560.
37. Lass-Florl C, Speth C, Kofler G, et al. Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method. Int J Antimicrob Agents 2003; 21: 229-233.
38. Greene RE, Mauskopf J, Roberts CS, et al. Comparative costeffectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. Am J Health Syst Pharm 2007; 64: 2561-2568.
39. Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007; 55: 287-299.
40. da Silva Ferreira ME, Malavazi I, Savoldi M, et al. Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr Genet 2006; 50: 32-44.
41. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: Phasespecific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-4340.
42. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. Emerg Infect Dis 2004; 10: 14-19.
43. Nascimento AM, Goldman GH, Park S, et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother 2003; 47: 1719-1726.
44. Singh N. Invasive aspergillosis in organ transplant recipients: New issues in epidemiologic characteristics, diagnosis, and management. Med Mycol 2005; 43 (Suppl. 1): S267-270.
45. Bakare N, Rickerts V, Bargon J, Just-Nubling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003; 46: 19-23.
46. Cimon B, Symoens F, Zouhair R, et al. Molecular epidemiology of airway colonisation by Aspergillus fumigatus in cystic fibrosis patients. J Med Microbiol 2001; 50: 367-374.
47. Pressler T, Frederiksen B, Skov M, et al. Early rise of antipseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection - a case control study. J Cyst Fibros 2006; 5: 9-15.
48. Mensi M, Salgarello S, Pinsi G, Piccioni M. Mycetoma of the maxillary sinus: Endodontic and microbiological correlations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 119-123.